Armune BioScience, Inc. Announces Appointment of New Chief Financial Officer

Share Article

New CFO for Armune BioScience after completing the first close of $2.5 Million Series A financing round.

After recently completing the first close on a $2.5 million Series A financing round, Armune BioScience, Inc. today announced the appointment of Susan J. Crookston to the position of Chief Financial Officer (CFO) to continue the company’s preparation for the launch of Apifiny™, its innovative, non-PSA blood test to aid in the early detection of prostate cancer.

"As Armune raises additional capital and prepares to launch Apifiny, we are excited to have Sue Crookston join our team as CFO. She brings significant financial experience in early-stage life science companies and we look forward to the complementary strengths she will bring to our team,” said David A. Esposito, President and CEO.

Sue joined the Armune team in September 2014 to prepare for the Series A round and support the transition of Jim Johnson as outgoing CFO. Esposito said, “We are thankful for the efforts of Jim Johnson in supporting the company since its founding in 2008 and through the transition as we prepare for the launch of Apifiny, our first diagnostic assay.”

Sue has more than 20 years of experience in various financial and human resource roles within the life sciences market, including senior and management team experience at two start-up companies - Afmedica and most recently with CeeTox, Inc. Sue also worked for Apjohn Ventures as the Finance Director, leading a number of key initiatives. Prior to working for start-ups, Sue held various financial leadership and analyst roles in The Upjohn Company, Pharmacia & Upjohn and Pfizer.

Eli Thomssen, Chief Business Officer, commented on the appointment of Sue while attending the J.P. Morgan 33rd Annual Healthcare Conference in San Francisco, CA, “We are seeing great interest in our technology from the investment community and Sue will play a critical role in positioning the company for success as we raise additional capital and prepare to launch our first diagnostic assay. We appreciate her hard work and commitment to Armune.”

Armune BioScience is focused on commercial execution in support of the launch of Apifiny and raising additional funds to complete the $2.5M Series A round. The first close of that round was announced earlier.

About Armune BioScience (http://www.armune.com)
Armune BioScience, Inc. is a medical diagnostics company formed to develop and commercialize unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. The Company was founded by the Apjohn Group, LLC, a business accelerator founded by experienced healthcare executives that brings together valuable resources of management talent and angel/seed financing, and a group of experienced life science professionals. Armune was incorporated as a Delaware Corporation with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI.

Contact:
Larry Eiler
Eiler Communications
Phone: 734 761 3399
Cell 734 646 6593
larry(at)eilerpr(dot)com

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Larry Eiler
Visit website